BMY 45778

The Uses of BMY 45778

BMY 45778 is an agonist for IP receptor to up-regulate the expression of C?/EBPβ and C?/EBPδ.

What are the applications of Application

BMY 45778 is a partial agonist at IP prostacyclin receptors

Definition

ChEBI: BMY 45778 is a bisoxazole. It has a role as a partial prostacyclin agonist.

Biological Activity

Non-prostanoid prostacyclin mimetic that acts as a partial agonist at IP 1 prostacyclin receptors. Potently inhibits platelet aggregation in vitro (IC 50 = 27-35 nM).

Biochem/physiol Actions

BMY 45778 is a non-prostanoid prostacyclin agonist.

References

[1]. seiler sm, brassard cl, federici me, et al. [3-[4-(4,5-diphenyl-2-oxazolyl)-5-oxazolyl]phenoxy]acetic acid (bmy 45778) is a potent non-prostanoid prostacyclin partial agonist: effects on platelet aggregation, adenylyl cyclase, camp levels, protein kinase, and iloprost binding. prostaglandins, 1997, 53(1): 21-35.
[2]. wise h, qian ym, jones rl. a study of prostacyclin mimetics distinguishes neuronal from neutrophil ip receptors. eur j pharmacol, 1995, 278(3): 265-269.